Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Appili Therapeutics Inc. has showcased promising results for its ATI-1701 vaccine candidate, which offers full protection against tularemia in animal models for up to a year. The company has secured a $14 million funding commitment from the United States Air Force Academy to advance ATI-1701 towards FDA submission in 2025.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.
